Employee benefits must go beyond the medical plan

Estimated reading time: 5 minutes · Last updated: 22 September 2026

Employee benefits strategy today means more than a medical plan: employers should wrap core coverage with meaningful ancillary and supplemental products, transparent broker compensation and sustained employee communication to control costs and protect staff. As first reported by Insurance Business, John Feeney, Vice President of Group Sales & Market Development at Renaissance Benefits in Washington D.C., says employers must build that wrapper deliberately rather than react to high-cost therapies alone. Feeney points to market shifts — from GLP-1 coverage falling among employers to new scrutiny of broker commissions — and argues brokers should provide data, design advice and year‑round engagement so benefit decisions preserve trust as well as balance sheets.

The conversation shifts from, can we cover everything, to how do we provide the right mix of coverage and financial protection,

John Feeney, Vice President of Group Sales & Market Development, Renaissance Benefits

Why GLP-1 decisions forced a rethink of benefits

Two recent developments crystallise the problem employers now face: rapidly rising demand for high-cost therapies such as GLP-1 drugs, and visible employer reactions to those costs. Business Group on Health data show employer coverage of GLP-1 weight‑loss drugs declined from 72 percent in 2025 to 60 percent in 2026, a roughly 12 percentage point drop that has pushed the question from if to how benefits should change.

Starbucks' public decision to withdraw coverage for these drugs served as a flashpoint, but John Feeney cautions against treating single employers' choices as universal policy. Instead, he says, employers must weigh demographics, workforce demand and utilization data when deciding whether to add, limit or exclude coverage.

The practical consequence is that benefits strategy must allow flexible responses to new therapies: a decision framework that weighs prescription cost against likely downstream savings in surgeries, testing or other treatments, and that can be explained to employees to preserve trust.

Brokers' role is widening — from plan design to communication and fee transparency

Feeney says brokers still spend the bulk of their time on medical plan design — he estimates 90 to 95 percent of their bandwidth goes to those discussions — but employers now expect more from them. That means brokers must combine plan design with utilization data, market intelligence and an ongoing communications programme that explains tradeoffs to employees.

Compensation transparency is part of that expanded mandate. Feeney notes class action lawsuits filed at the end of 2025 have accelerated scrutiny of broker compensation for voluntary benefits. He describes a move among some larger firms away from elevated first‑year 'heap commissions' toward flat, year‑over‑year structures and, in larger cases, fee‑based models. In smaller, under‑$1,000 markets, commissions still dominate but fee arrangements are increasingly plausible.

Where brokers disclose whether they are paid commissions or fees, and demonstrate the advisory value they add — data analysis, better communication, tailored design — employers are better positioned to judge net financial impact rather than react to headline costs alone.

Supplemental products can ‘wrap’ the medical plan and reduce shock

Feeney's prescription is concrete: surround the medical plan with supplemental and ancillary products that are low cost relative to the core plan but high value at the point of need. He cites a Bankrate 2026 finding that 59 percent of Americans lack $1,000 for an unexpected medical bill to argue supplemental pay‑outs meet real financial gaps employees face.

Renaissance's RenSecure Health is given as an example: it is a diagnosis‑based supplemental product mapped to more than 13,000 ICD‑10 diagnoses rather than a fixed schedule. For large groups Renaissance can run a retrospective claims report showing what RenSecure would have paid in the prior plan year, offering a concrete demonstration of prospective value at quoting.

The product also automates claims payment: when a paid medical claim matches a covered diagnosis the administrator notifies Renaissance and benefits are deposited directly to a member's Venmo, PayPal, or bank account, reducing friction and improving utilization.

Build a repeatable evaluation framework for the next pharmaceutical breakthrough

GLP-1s will not be the last expensive innovation employers confront. Feeney points to a pipeline that includes orexin sleep drugs and says carriers must judge both cost and clinical benefit: does a drug reduce downstream interventions, procedures or testing in a way that offsets its price?

That implies a data‑driven process brokers and carriers should establish now: quantify likely utilization, model total cost of care with and without coverage, and test communication scenarios so decisions can be explained to employees. Feeney argues firms that build this analytical muscle and client relationships before the next breakthrough arrive will make strategic, not reactionary, coverage choices.

For employers that lack internal analytics, brokers who can deliver utilization benchmarking across clients — and who can show how a supplemental wrapper would have performed historically — claim a clear advisory role.

How this strategy could play out

The bottom line

Employers confronting high‑cost therapies and tighter scrutiny of broker pay should treat benefits strategy as a system, not a single plan decision. Wrap the medical plan with targeted supplemental products, insist on transparent compensation and invest in year‑round communication so employees understand value. Brokers that can show retrospective modelling, explain tradeoffs and offer a repeatable evaluation framework for new drugs will be the advisers employers rely on when the next breakthrough arrives.

What to watch

• Watch employer open‑enrollment decisions on GLP‑1 coverage; no date has been set.
• Watch carriers' policy updates and coverage decisions for emerging drugs such as orexin sleep therapies; no date has been set.
• Watch outcomes from the class action lawsuits filed at the end of 2025 for effects on broker compensation practices; no date has been set.